CD38 and plasma cell myeloma: By binding to CD38, which is highly expressed on myeloma cells, isatuximab enhances immune-mediated destruction of malignant plasma cells and disrupts their survival pathways, demonstrating significant efficacy in RRMM, particularly when combined with immunomodulatory drugs, proteasome inhibitors, or corticosteroids [1, 2].